TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00876187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 20 mg IV
Description: 2 IV administrations of tanezumab 20 mg at an 8 week interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for naproxen
Description: Oral placebo for naproxen twice a day for 16 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg IV
Description: 2 IV administrations of tanezumab 10 mg at an 8 week interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for naproxen
Description: Oral placebo for naproxen twice a day for 16 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg IV
Description: 2 IV administrations of tanezumab 5 mg at an 8 week interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for naproxen
Description: Oral placebo for naproxen twice a day for 16 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for tanezumab
Description: 2 IV administrations of placebo for tanezumab at an 8 week interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Oral naproxen 500 mg twice a day for 16 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for tanezumab
Description: 2 IV administrations of placebo for tanezumab at an 8 week interval

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for naproxen
Description: Oral placebo for naproxen twice a day for 16 weeks
Study: NCT04431570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The device is made in London, United Kingdom

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The device is made in London, United Kingdom

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: the device of sham stimulation was MagStim MC-P-B70 placebo butterfly coil
Study: NCT01353027

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-6002
Description: Single intravenous administration
Study: NCT05775185

Intervention type: RADIATION
Intervention: Orbital radiotherapy
Description: Low dose fractionated orbital radiotherapy, total dose 20 Gy in 2-week period.
Study: NCT03096964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free walking training
Description: The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking training
Description: The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
Study: NCT04219345

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Both groups will undergo the same protocol of twelve sessions of twenty minutes of tDCS associated with mindfulness, where only the type of received electric current is varied (active or simulated sham type). The twelve sessions will be performed in three sessions per week for four weeks, and mindfulness practice at home will be encouraged on days when the intervention is not administered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Both groups will undergo the same protocol of twelve sessions of twenty minutes of tDCS associated with mindfulness, where only the type of received electric current is varied (active or simulated sham type). The twelve sessions will be performed in three sessions per week for four weeks, and mindfulness practice at home will be encouraged on days when the intervention is not administered.
Study: NCT03767075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg, administered IV, once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: 20 mg administered orally, once daily (QD) continuously in 28-day cycles.
Study: NCT00251732

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole , placebo, placebo
Description: 20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime
Study: NCT01352000

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Approximately 3400 quitline clients will be randomized to one of three conditions at the point of their 2-week follow-up call.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Approximately 3400 quitline clients will be randomized to one of three conditions at the point of their 2-week follow-up call.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Approximately 3400 quitline clients will be randomized to one of three conditions at the point of their 2-week follow-up call.
Study: NCT03351725

Intervention type: DEVICE
Intervention: peripheral venous catheter (PVC)
Description: No intervention is made only in situ swab from the PVC
Study: NCT02721329

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APAP
Description: Automatic Continuous Positive Airway Pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APAP with SensAwake
Description: Automatic Continuous Positive Airway Pressure with SensAwake enabled. SensAwake is a pressure relief technology that detects the transition from sleep to wake, and promptly reduces the pressure during wakeful periods.
Study: NCT03291496

Intervention type: OTHER
Intervention: Blood Collection Preterm
Description: Blood will be collected on day 4 of life and then approximately every 3 days until 21 days of life. Thereafter, one sample will be collected weekly until discharge. For preterm neonates that have suspected sepsis an additional sample will be collected within 24-48 hours of the initial sepsis evaluation.

Intervention type: OTHER
Intervention: Blood Collection Term
Description: A single 250 µl blood sample will be collected once the term neonate is \>24 hours old.

Intervention type: OTHER
Intervention: Adult Blood collection
Description: One Time 1 ml of whole blood collected
Study: NCT02157883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling
Description: Blood samples taken pre and post dosing with AZD9291+/- itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
Study: NCT04809480

Intervention type: DIAGNOSTIC_TEST
Intervention: Fungal rhinosinusitis
Description: Pathology examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Fungal rhinosinusitis
Description: Pathology examination
Study: NCT02677883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manometry-guided thoracentesis
Description: Arm I will undergo a standard of care therapeutic thoracentesis procedure, and in addition include pleural pressure monitoring (via an FDA-approved digital manometer) which is also standard of care but left at the discretion of physicians as per expert recommendations. In this group, the procedure will be stopped when the patient develops symptoms or when all the fluid has been removed, and will also be stopped if the pressure begins to fall quickly in the fluid collection.
Study: NCT03767075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: 1050 mg administered IV for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)
Study: NCT04059770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of L-AmB
Description: (i) single IV dose of 10 mg/kg of L-AmB on day 1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 doses of L-AmB
Description: (ii) IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 weeks of L-AmB
Description: (iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.
Study: NCT03851900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teethmate Desensitizer (TM)
Description: Desensitizing agent will be applied to sensitive teeth.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil SE Bond 2
Description: Desensitizing agent will be applied to sensitive teeth.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Placebo will be applied to sensitive teeth as a negative control.
Study: NCT03481114

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PET-based, dose-painted, accelerated chemoradiotherapy
Description: Patients in this arm will receive a more personalized and shorter radiation therapy treatment course utilizing PET imaging.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemoradiotherapy
Description: Patients in this arm will receive a standard radiotherapy course.
Study: NCT01032915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 300mg s.c weekly for 3 weeks then every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 300mg s.c at baseline and Week 2 then every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 150mg s.c at baseline and Week 2 then every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c weekly for 3 weeks then every 2 weeks
Study: NCT02514915

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery
Description: Radiation therapy
Study: NCT00442780

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB014
Description: oral administration of BIIB014 per dose, schedule,and duration specified in protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB014
Description: oral administration of BIIB014 per dose, schedule,and duration specified in protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB014
Description: oral administration of BIIB014 per dose, schedule,and duration specified in protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB014
Description: oral administration of BIIB014 per dose, schedule,and duration specified in protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014
Study: NCT01226550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cytoreductive surgery and HIPEC
Description: The most complete cytoreductive surgery possible (ideally macroscopically complete) followed by a closed-abdomen hyperthermic intraoperative peritoneal chemotherapy (HIPEC), using a closed circuit connected to the self-regulating Cavitherm machine (EEC certified). This perfusion apparatus records temperature, flow, and pressure for 90 minutes at real temperature (42-43°C).~The dialysate is made up of peritoneal dialysis fluid containing 0.7 mg/kg of MMC and increasing doses of irinotecan added to the dialysate the last 30 minutes of the HIPEC.~Potentiation of irinotecan using an intravenous FUFOL perfusion at least 1hour before HIPEC (1st dose level: 10 mg/m² of folinic acid, then 200 mg/m² of 5-FU; 2nd dose level: 20 mg/m² of folinic acid, then 400 mg/m² of 5-FU).
Study: NCT01536600

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: The insulin dose and regimen was individualised at the physician's discretion
Study: NCT03853785

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR vaccine
Description: Intralesional injection of 0.5 ml MMR vaccine in the largest lesion . Injections will be repeated into the same lesion every 2 weeks for a maximum of three treatment sessions.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Candida antigen
Description: Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by an insulin syringe in the largest wart at the first visit. Injections will be repeated for all patients into the same lesion every 2 weeks for a maximum of three treatment sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Podophyllin
Description: It will be applied to the wart by using a cotton tipped swab once a week . The procedure will be limited to 10 cm2 per session .Surrounding skin will be protected by Vaseline. Podophyllin will be washed 4 hour after application . The procedure will be repeated every week till 6 weeks .
Study: NCT00892385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyamine
Description: For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyamine
Description: For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study: NCT00142467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT00238251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib
Description: Once daily during days 1-28

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: Once daily on days 1-21

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Whole brain radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Whole brain radiotherapy
Study: NCT00913900

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous CD133+ cells
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: autologous CD133+ cells
Description: Intramuscular injection
Study: NCT03972969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facility-based structured exercise
Description: Structured exercise program in a facility with instruction and encouragement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based structured exercise
Description: Structured exercise program in the home with instruction and encouragement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Provision of general information about a variety of topics
Study: NCT04413253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lifitegrast 5% Ophthalmic Solution
Description: To reduce signs and symptoms of dry eye disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution
Description: To determine the outcomes of reduction of signs and symptoms of dry eye disease with DEXTENZA as an added therapy, in addition to Xiidra therapy.
Study: NCT03024554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the Bifurcated Multilayer Flow Modulator
Study: NCT04654494

Intervention type: PROCEDURE
Intervention: Total proctocolectomy
Description: excision of the whole large bowel including colon and rectum and end ileostomy fashioning

Intervention type: PROCEDURE
Intervention: Total colectomy
Description: excision of the colon with preservation of the rectum

Intervention type: PROCEDURE
Intervention: Segmental colectomy
Description: excision of a segment of colon
Study: NCT01211600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Staples
Description: Interrupted Ethicon Staples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
Study: NCT00779649

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MoviPrep Kit
Description: Diet: At noon the day prior to the procedure, patients will begin a clear liquid diet. Patient will discontinue any ingestion by mouth 4 hours prior to the procedure.~Purgative: Starting at 6pm the evening before the procedure, patient will ingest 250 ml of MoviPrep® at 15 minute intervals until 1 liter is consumed. Following this, an additional 500 ml (approximately 16 oz) of clear liquids will be consumed. The next day, 6 hours before the procedure, the patient will repeat ingestion of one liter MoviPrep® over the course of an hour, again ingesting 250 ml at 15 minute intervals. Patient will then ingest an additional 500 ml (approximately 16 oz) of clear liquid following the MoviPrep® consumption.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HalfLytely and Bisacodyl Tablets Bowel Prep Kit
Description: Diet: Patients will refrain from solid food and have only clear liquids starting 8 am on the day before colonoscopy. In addition, patients will consume nothing by mouth, except clear liquids, from the time the preparation is completed until midnight. Patients will be instructed not to eat or drink anything from midnight until after the colonoscopy is completed.~Purgative: At noon on the day prior to colonoscopy patients will swallow (not chew or crush) 2 bisacodyl delayed release tablets (10 mg). Once the initial bowel movement has occurred (1 - 6 hours after taking the bisacodyl tablets), or if there has been no bowel movement, not more than 6 hours after ingestion of the bisacodyl tablets patients will then drink the reconstituted HalfLytely® solution over 1 hour and 20 minutes. Patients will drink one 8-oz glass every 10 minutes until the two liters is completed
Study: NCT00877812

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arm 1 glycine and leucine
Description: Arm 1 glycine and leucine: A subset of 14 participants out of the total enrolled participants with an adequate nutritional status will undergo the tracer infusion of glycine and leucine amino acids protocol while an adequate vitamin pyridoxine, B6 status. After the first infusion each participant will then begin a diet low in vitamin B6 (\<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by a repeat of fasting blood sampling and tracer infusion protocol.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arm 2 Intervention of Serine and methionine infusion
Description: Arm 2 Intervention of Serine and methionine infusion: A subset of 14 participants out of the total enrolled participants. Received an adequate nutritional status will undergo the tracer infusion of methionine and serine amino acids protocol while in adequate vitamin pyridoxine, B6 status. After the first infusion each subject will then begin a diet low in vitamin B6 (\<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by repeat of fasting blood sampling and tracer infusion protocol.
Study: NCT00911352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frozen gel glove (Elasto-Gel Mitten)
Description: Gel glove is frozen for \> 3 hours at -5 to -30°C prior to use. Each patient wears a triple glove set (surgical glove overlaid with cotton glove, overlaid with gel glove) on their intervention hand. Gloves are worn for duration of infusion (15 mins pre, 60 minutes intratreatment and 15 mins post) to ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails.
Study: NCT02888093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)
Study: NCT03422315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: injection;2mg/kg;single-dose
Study: NCT01401725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Order Entry System + CDSS
Description: Physicians at this hospital will use an Electronic Order Entry System plus a computerized decision support system (CDSS) to support VTE prophylaxis decisions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Order Entry System Only
Description: Physicians at this hospital will use an Electronic Order Entry System

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Physicians at this hospital will practice usual care (no Electronic Order Entry System and no CDSS for VTE prophylaxis decisions)
Study: NCT02949180

Intervention type: DEVICE
Intervention: Five minutes puls wave recording
Description: iPhone will be positioned on the index finger for five minutes to record a pulse wave

Intervention type: DEVICE
Intervention: Five minutes puls wave recording
Description: iPhone will be positioned on the index finger for five minutes to record a pulse wave